Accueil>>Signaling Pathways>> Angiogenesis>> Integrin>>Integrin modulator 1

Integrin modulator 1

Catalog No.GC61613

Le modulateur d'intégrine 1 est un agoniste d'intégrine α4β1 puissant et sélectif, avec une IC50 de 9,8 nM pour la liaison RGD α4β1.

Products are for research use only. Not for human use. We do not sell to patients.

Integrin modulator 1 Chemical Structure

Cas No.: 2023788-32-9

Taille Prix Stock Qté
10mM (in 1mL DMSO)
357,00 $US
En stock
5 mg
324,00 $US
En stock
10 mg
538,00 $US
En stock
25 mg
1 020,00 $US
En stock
50 mg
1 576,00 $US
En stock
100 mg
2 318,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM[1].

Integrin modulator 1 (2-10 μg/mL; 30 min) significantly increases Jurkat E6.1 cell adhesion[1].Integrin modulator 1 (1-100 nM; 1 h) strongly and significantly increases ERK1/2 phosphorylation in Jurkat E6.1 cells[1].Integrin modulator 1 (1 nM-10 μM; 30 min) significantly increases the binding of HUTS-21 antibody to Jurkat E6.1 cells in a concentration-dependent manner[1].

[1]. Baiula M, et, al. New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins. J Med Chem. 2016 Nov 10;59(21):9721-9742.

Avis

Review for Integrin modulator 1

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Integrin modulator 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.